Menu
The University of Oklahoma Health Sciences Center has launched a research collaboration with Pure MHC, LLC an innovative biotechnology company, to work toward the development of a vaccine for the COVID-19 virus.
“With OU, we are acquiring the actual COVID-19 virus, and we will infect cells and look for the targets on the infected cells. We will use those targets to either develop a vaccine or to directly target them with something like monoclonal antibodies.”
Curtis McMurtrey, PhD,
Director of Immuno-Proteomics for Pure MHC and a graduate of the OU Health Sciences Center.
OKLAHOMA CITY, OK AND AUSTIN, TX – The University of Oklahoma Health Sciences Center has launched a research collaboration with Pure MHC, LLC an innovative biotechnology company, to work toward the development of a vaccine for the COVID-19 virus.
March 20, 2020
February 13, 2019
Emergent Technologies, Inc. announced today that its portfolio company,
Receptor Logic, has entered into an exclusive License Agreement with Xencor,
Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing
engineered monoclonal antibodies for autoimmune diseases, asthma and
allergic diseases, and cancer.
ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC)
announced an agreement with Pure MHC, an Emergent Technologies portfolio
company, for development of a novel assay for quality control that will be an
important component of ImmunoCellular’s ICT-107 phase 3 registrational
clinical program in newly diagnosed glioblastoma, anticipated to begin in the
second half of 2015.
June 22, 2015
A recent cancer study performed by the Washington University School of
Medicine in St. Louis has garnered significant interest from the science and
medical community. This research, led by Dr. Beatriz Carreno, tested the
ability of a personalized cancer vaccine to assist the immune system’s
effectiveness in attacking a patient’s specific tumor.
April 1, 2015
PhosImmune Inc. and PureMHC LLC today announced they have entered into a
license and collaboration agreement to develop novel antibody-based
immunotherapies designed to target cancers.
October 21, 2014
Pure MHC, LLC
Administrative Office
7500 Rialto Blvd.
Building Two, Suite 260
Austin, TX 78735
Research Laboratory
655 Research Parkway
Suite 556
Oklahoma City, OK 73104